DORC International and WEFIS GmbH announced Jan. 12 that they have formed a new strategic partnership to develop cataract surgical instruments for use with DORC’s EVA platform and EQUIPHACO range of disposable devices.
Rayner Launches Blue Light-Filtering IOL in Europe, Gets FDA Green Light to Begin US Trial of Trifocal Lenses
UK-based ophthalmic company Rayner announced Jan. 5 that it had launched the RayOne Hydrophobic BLF, the company’s first blue light-filtering IOL, in Europe. The lens is available from 0.0 diopters to +32.0 diopters in countries accepting CE-marked products. It expands the RayOne portfolio to eight models. Rayner CEO Tim Clover said of the launch: “Over a third of all lenses …
Rayner acquires Omidria to expand surgical offering in USA and Europe
Rayner Surgical Group (‘Rayner’) and Omeros Corporation (‘Omeros’) are delighted to announce the transfer of Omeros’ ophthalmology assets, including OmidriaTM, to Rayner. This will enable the creation of a significant commercial, regulatory and marketing infrastructure in the US, with a broad range of products, including intraocular lenses (IOLs), for cataract surgeons. OmidriaTM has excellent and substantial clinical data supporting the maintenance …
Oertli Instrumente Acquires Majority Interest in Ophthalmic Instrument Maker Domedics AG
Oertli Instrumente announced it has acquired the majority of shares of Dattwil, Switzerland-based Domedics AG. Terms of the deal were not disclosed.https://eyewire.news/news/oertli-instrumente-acquires-majority-interest-in-ophthalmic-instrument-maker-domedics-ag
Oertli Launches Updated Faros Surgical Platform
Oertli has updated its Faros surgical platform with new LED technology. The compact device for anterior and posterior segment surgery provides 45% more light output, and ensures optimal illumination and visualization, according to a company news release. Oertli’s Faros device performs cataract, vitrectomy, and glaucoma surgery. The precise flow control of the peristaltic pump is designed to make the surgeon’s work simple …
Cataract surgery lowers IOP, medication use
Patients with ocular hypertension may benefit from cataract surgery, according to findings published in the American Journal of Ophthalmology.“Studies suggest that cataract surgery lowers IOP, and that this reduction is generally proportional to presurgical IOP. As well, several papers report a decrease in ocular hypotensive medications with cataract surgery,” Steven L. Mansberger, MD, MPH, ophthalmologist at Legacy Health in Portland, …
Adjustable IOL Maker RxSight Launches $118 Million IPO
RxSight, of Aliso Viejo, California, launched on July 30 a $118 million initial public offering of 7.35 million shares of common stock at a price of $16 per share. Shares are trading on the Nasdaq under the symbol RXST.
Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilateral Cataract Surgery
Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to control group (58.6 vs. 79 percent) and showed larger improvements in Meibomian Gland Score (MGD) than control group (107 vs. 66 percent).